Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute Purchases 51 HiSeq Machines from Illumina

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Broad Institute has purchased 51 HiSeq 2000 instruments from Illumina.

The HiSeq 2000 was launched earlier this year and is the latest version of Illumina's sequencing technology, providing a variety of upgraded features over its Genome Analyzer. At the time of its launch, the firm announced that Chinese genome center BGI had ordered 128 of the new systems.

Illumina said that the HiSeq instruments will replace an equal number of Genome AnalyzerIIx systems at the Broad as the institute upgrades and expands its sequencing capacity. Illumina added that it expects to ship the systems to the Broad over the next several quarters.

"We believe that the HiSeq 2000s will significantly increase our capabilities in high-throughput genomics, as our experience with early access instruments has already produced multiple runs in excess of 250 Gb of data and yielded significant improvements in lab workflow," Robert Nicol, director of sequencing operations and technology development at the Broad Institute, said in a statement.

Illumina did not disclose the purchase price for the 51 systems.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.